EUVIMEDEUVIMED entdecken
Crossref

In silico strategies to recognize pharmacological constraints contrary to COX-2 and 5-LOX

Kumari Neha, Gagandeep Singh, Mrityunjay Singh iD, Shailendra Asthana, Sharad Wakode

Journal of Biomolecular Structure and Dynamics · 2026

DOI: 10.1080/07391102.2024.2425404 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biomolecular Structure and Dynamics, 2026. Verfasst von Kumari Neha und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), Delhi Pharmaceutical Sciences and Research …. Hauptthemen laut MEDLINE: Cyclooxygenase 2, Arachidonate 5-Lipoxygenase, Lipoxygenase Inhibitors, Cyclooxygenase 2 Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

COX-2 and 5-LOX are major enzymes implicated in inflammatory processes and have a crucial role in the pathogenesis of inflammatory disorders and malignancies. Designing antagonists that may concurrently interact with several receptors is a viable technique; thus, blocking these two targets with a single chemical compound might provide an efficient therapeutic approach. In-silico approaches have been employed to find polypharmacological inhibitors, especially for drug repurposing and multitarget drug design. Here, virtual screening of designed oxygen-containing heterocyclic series from prior literature was used to locate a feasible dual inhibitor against COX-2 and 5-LOX. Among these, 5-phenyl-2-(pyridin-3-yl)oxazol-4-yl cyclohexyl(methyl)sulfamate (N14) and 5-phenyl-2-(pyridin-4-yl)oxazol-4-yl benzenesulfonate (N16) was found to more promising with good interaction energy against COX-2 (-9.5 and -9.4 kcal/mol) and 5-LOX (-8.6 and -7.6 kcal/mol). Additionally, it also fulfilled the ADME/T parameters revealed to be drug-like, as anticipated by Lipinski's rule of five and Veber's rule. Furthermore, the molecular dynamics, free binding energy and post-processing analysis indicate N14 and N16 appears as a promising candidates with a novel molecular scaffold that could be examined further as a polypharmacological anticancer therapeutic candidate to explore further for the development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclooxygenase 2Arachidonate 5-LipoxygenaseLipoxygenase InhibitorsCyclooxygenase 2 InhibitorsMolecular Docking SimulationHumansMolecular Dynamics SimulationDrug DesignProtein BindingComputer SimulationBinding Sites

Stichwörter der Autor:innen

5-LOXADME/TCOX-2In silicoMD simulationfree-energymolecular docking

Substanzen

Cyclooxygenase 2Arachidonate 5-LipoxygenaseLipoxygenase InhibitorsCyclooxygenase 2 Inhibitors

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), Delhi Pharmaceutical Sciences and Research University, New Delhi, India.
  • Computational Biophysics and CADD Group, Computational and Mathematical Biology Centre (CMBC), Translational Health Science and Technology Institute (THSTI), Faridabad, Haryana, India.

ORCID-Profile: Mrityunjay Singh

Zitieren

APA

Neha, K., Singh, G., Singh, M., Asthana, S., & Wakode, S. (2026). In silico strategies to recognize pharmacological constraints contrary to COX-2 and 5-LOX. Journal of Biomolecular Structure and Dynamics. https://doi.org/10.1080/07391102.2024.2425404

Vancouver

Neha K, Singh G, Singh M, Asthana S, Wakode S. In silico strategies to recognize pharmacological constraints contrary to COX-2 and 5-LOX. Journal of Biomolecular Structure and Dynamics. 2026. doi:10.1080/07391102.2024.2425404

BibTeX
@article{Neha2026,
  author = {Neha, Kumari and Singh, Gagandeep and Singh, Mrityunjay and Asthana, Shailendra and Wakode, Sharad},
  title = {In silico strategies to recognize pharmacological constraints contrary to COX-2 and 5-LOX},
  journal = {Journal of Biomolecular Structure and Dynamics},
  year = {2026},
  doi = {10.1080/07391102.2024.2425404}
}
Kostenlos starten →